PIK3CA and colorectal carcinoma: Especially, targeted therapies can be used for patients with stage IV CRC, and discussions are still ongoing as to whether PIK3CA mutations including those present at the exon 20 are predictive biomarkers of response to anti-EGFR monoclonal antibodies 41.